Brought to you by 
Telesta Therapeutics raises $28.3mm through private placement
20 Aug 2015
Executive Summary
Telesta Therapeutics Inc. (developing MCNA (Mycobacterium phlei cell wall-nucleic acid complex) for non-muscle invasive bladder cancer) raised $28.3mm through the private sale of 109mm common shares at $0.26 (market average).Consonance Capital Investors purchased almost half of the shares (and now holds a 19.96% stake), and was joined by Boxer Capital (of Tavistock Life Sciences) and Omega Funds, along with members of Telesta's senior management team and board of directors.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Financing
- Private Investment in Public Equity
- Private Placement
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Telesta Therapeutics raises $28.3mm through private placement
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice